Results 81 to 90 of about 566,656 (110)

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma

New England Journal of Medicine, 2017
G. Long, A. Hauschild, M. Santinami, V. Atkinson, M. Mandalà, V. Chiarion-Sileni, J. Larkin, M. Nyakas, C. Dutriaux, A. Haydon, C. Robert, L. Mortier, J. Schachter, D. Schadendorf, T. Lesimple, R. Plummer, R. Ji, Ping-Kuan Zhang, B. Mookerjee, J. Legos, R. Kefford, R. Dummer, J. Kirkwood   +22 more
semanticscholar   +1 more source

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

The Lancet Oncology, 2009
R. Stupp, M. Hegi, W. Mason, M. J. van den Bent, M. Taphoorn, Robert C. Janzer, S. Ludwin, A. Allgeier, B. Fisher, K. Bélanger, P. Hau, A. Brandes, J. Gijtenbeek, C. Marosi, C. Vecht, K. Mokhtari, P. Wesseling, S. Villá, E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J. G. Cairncross, R. Mirimanoff   +23 more
semanticscholar   +1 more source

Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684

Journal of Clinical Oncology, 2023
PURPOSE Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or regionally metastatic (N1) melanoma.
J. M. Kirkwood, M. H. Strawderman, M. Ernstoff, T. J. Smith, E. Borden, R. H. Blum   +5 more
semanticscholar   +1 more source

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.

The Lancet Oncology, 2022
BACKGROUND Pembrolizumab is a standard-of-care for advanced non-small-cell lung cancer (NSCLC). We assessed pembrolizumab as adjuvant therapy for completely resected stage IB-IIIA NSCLC.
M. O'Brien, L. Paz-Ares, S. Marréaud, U. Dafni, K. Oselin, L. Havel, E. Esteban, D. Isla, A. Martínez-Martí, M. Faehling, M. Tsuboi, J. Lee, K. Nakagawa, Jing Yang, A. Samkari, S. Keller, M. Mauer, N. Jha, R. Stahel, B. Besse, S. Peters   +20 more
semanticscholar   +1 more source

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

The Lancet, 2021
BACKGROUND Novel adjuvant strategies are needed to optimise outcomes after complete surgical resection in patients with early-stage non-small-cell lung cancer (NSCLC).
E. Felip, N. Altorki, Cai-Cun Zhou, T. Csőszi, I. Vynnychenko, O. Goloborodko, A. Luft, A. Akopov, A. Martínez-Martí, H. Kenmotsu, Yuh-Min Chen, A. Chella, S. Sugawara, D. Voong, Fan Wu, J. Yi, Yu Deng, M. Mccleland, E. Bennett, B. Gitlitz, H. Wakelee   +20 more
semanticscholar   +1 more source

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer.

New England Journal of Medicine
BACKGROUND Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking. METHODS In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected ...
K. Courneya, J. Vardy, Christopher J. O'Callaghan, Sharlene Gill, Christine M. Friedenreich, Rebecca K. S. Wong, H. Dhillon, Victoria M. Coyle, N. Chua, Derek J. Jonker, P. Beale, Kamal Haider, P. Tang, Tony Bonaventura, Ralph Wong, H. J. Lim, M. Burge, S. Hubay, M. Sanatani, Kristin L Campbell, F. Arthuso, Jane Turner, Ralph M. Meyer, M. Brundage, Patti O'Brien, Dong-Sheng Tu, C. M. Booth   +26 more
semanticscholar   +1 more source

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.

New England Journal of Medicine
BACKGROUND Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)-based detection of molecular residual disease may identify patients at high risk for recurrence after cystectomy who can benefit ...
T. Powles, Ariel G. Kann, D. Castellano, M. Gross-Goupil, Hiroyuki Nishiyama, S. Bracarda, Jørgen Bjerggaard Jensen, Lydia E Makaroff, Shusuan Jiang, J. H. Ku, S. H. Park, Òscar Reig Torras, Ding-Wei Ye, M. Maruzzo, A. Necchi, R. Morales-Barrera, E. Giunta, J. Lee, G. Tortora, Y. Ürün, Lukasz Dolowy, Dilek Erdem, Álvaro Pinto, Fabricio Grando, Wei Zou, Z. Assaf, J. Vuky, V. Degaonkar, Elizabeth E. Steinberg, J. Bellmunt, J. Gschwend   +30 more
semanticscholar   +1 more source

Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update

Journal of Clinical Oncology, 2021
PURPOSE To develop recommendations for adjuvant therapy for patients with resected stage II colon cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.
N. Baxter, E. Kennedy, E. Bergsland, J. Berlin, T. George, S. Gill, P. Gold, A. Hantel, L. Jones, C. Lieu, N. Mahmoud, Arden M. Morris, E. Ruíz-García, Y. You, J. Meyerhardt   +14 more
semanticscholar   +1 more source

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

Journal of Clinical Oncology, 2019
PURPOSE To update the ASCO clinical practice guideline on adjuvant endocrine therapy based on emerging data about the optimal duration of aromatase inhibitor (AI) treatment.
H. Burstein, C. Lacchetti, Holly Anderson, T. Buchholz, N. Davidson, K. Gelmon, S. Giordano, C. Hudis, Alexander J Solky, V. Stearns, E. Winer, J. Griggs   +11 more
semanticscholar   +1 more source

Sıçan adjuvant artrit modelinde, artrit süresine bağlı izole aort yanıtlarında değişiklikler ve Allopürinol`ün izole aort gevşeme yanıtlarına etkisi

2020
85
openaire   +1 more source